The global T lymphocyte activation antigen CD80 market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). CD80 is a costimulatory molecule that is known for its role in T-cell activation. It also regulates the activity of normal and malignant B cells. The major factor driving the demand for T lymphocyte activation antigen CD80 is the increasing prevalence of acute myelocytic leukemia (AML) across the globe.
According to the American Society of Clinical Oncology (ASCO), AML is uncommon and makes up about 1% of cancers. Additionally, in 2021, an estimated 20,240 people of all ages which include 11,230 men and boys and 9,010 women and girls was diagnosed with AML in the US. Furthermore, AML is the second most common type of leukemia diagnosed in adults and children, however, most cases occur in adults and makes up 31% of all adult leukemia cases. Moreover, the average age of diagnosis is 68 years, however, it can be diagnosed at any age. Hence, the increasing prevalence of AML is driving the demand for T lymphocyte activation antigen CD80 as it is used as immunotherapy by identifying neoplastic cells and sparing healthy tissue which in turn is driving the growth of the market.
To Request a Sample of our Report on T Lymphocyte Activation Antigen CD80 Market: https://www.omrglobal.com/request-sample/t-lymphocyte-activation-antigen-cd80-market
Some major players in the market include Bristol-Myers Squibb Co, and KAHR Medical Ltd, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2021, AstraZeneca announced positive high-level results from the Phase III Himalaya clinical trial of Imfinzi (durvalumab) plus tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (HCC) patients. Tremelimumab is an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Bristol-Myers Squibb Co, and KAHR Medical Ltd, among others.
(Get 15% Discount on Buying this Report)
A full Report of T Lymphocyte Activation Antigen CD80 Market is Available @ https://www.omrglobal.com/industry-reports/t-lymphocyte-activation-antigen-cd80-market
Global T Lymphocyte Activation Antigen CD80 Market Report by Segment
By Type
- Abatacept
- Abatacept Biosimilar
- CUE-201
- KAHR-102
- Others
By Application
- Metabolic Disorders
- Autoimmune Disorders
- Acute Myelocytic Leukemia
- Others
Global T Lymphocyte Activation Antigen CD80 Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
